通心络胶囊辅助治疗慢性肺源性心脏病临床效果观察

目的观察通心络胶囊辅助治疗慢性肺源性心脏病的临床效果。 方法选取2016年8月至2017年12月河南省人民医院收治的75例CPHD患者，依据随机数表法将其分为对照组(37例)和研究组(38例)。对照组患者接受常规治疗，研究组患者在常规治疗的基础上接受通心络胶囊辅助治疗。统计两组患者治疗总有效率，对比两组患者治疗前后LVEF、CO和ET－1、NO水平。 结果研究组患者治疗总有效率(94.73%)高于对照组(78.38%)，P<0.05；研究组患者治疗后LVEF、CO水平均低于对照组(P<0.05)；研究组患者治疗后ET－1水平低于对照组，NO水平高于对照组(P<0.05)。 结论通心络胶囊辅助治疗CPHD临床效果较好，可有效改善患者心功能和血管内皮功能，可在临床推广应用。

Clinical effect of tongxinluo capsule in the treatment of chronic pulmonary heart disease

ObjectiveTo observe the clinical effect of tongxinluo capsule in the treatment of chronic pulmonary heart disease. MethodsA total of 75 CPHD patients admitted to Henan Provincial People's Hospital from August of 2016 to December of 2017 were randomly divided into the control group (37 cases) and the study group (38 cases). The control group received routine treatment, and the study group received tongxinluo capsule as an assistant treatment on the basis of routine treatment. Total therapeutic efficiency of the two groups was calculated, and LVEF, CO and ET-1, NO levels were compared before and after treatment. ResultsThe total effective rate of the study group (94.73%) was higher than that of the control group (78.38%), and the difference was statistically significant (P<0.05). The levels of LVEF and CO in the study group were lower than those in the control group (P<0.05). The level of ET-1 in the study group was lower than that in the control group, and the level of NO in the study group was higher than that in the control group (P<0.05). ConclusionTongxinluo capsule has a good clinical effect in the adjuvant treatment of CPHD. It can effectively improve the cardiac function and vascular endothelial function of patients, and can be widely used in clinical practice.